Tonix Pharmaceuticals Holding Corporation (TNXP)

I encourage all stockholders to contact Tonix by email and phone (listed on Tonix website) to demand a forward split of at least10:1. Tonix owes us this forward split after they took away our shares!! Remember Tonix management personnel are living up on million dollar plus salaries and benefits while we have nothing but reduced share counts!!!

Also remember Tonix wants to sell $150,000,000 of our shares they took from us so they can maintain the rich life they are living!!!

Most likely powerwalker and associates are selling and buying as they don't want a 10:1 forward split. Tonix owes us some of our shares back!!

They maybe the ones shorting the stock!!

One of the BENEFITS of a small float?

Any demand can cause a 'spike' in the price
as the shares available (not tightly held) get harder
to get ahold of.

institutionals have to file 13F D G forms 45 days after end of quarter. August 15th required. A few may report early. Most file On the Last Day as per SEC requirements. Watch Fintel and or Whale Wisdom websites as you get closer to Aug 15th.
John k9uwa

Oh Yeah!!!
If it was at 70 I would understand who is selling... before approval
The moon... beautiful

Countdown to 08/15!!!!
Still much upside!!!

GLTA

🤣 🤣 🤣

Powerwalker can't read English. I stated all that agree put a thumbs up. I suspect powerwalker could be directly afflilated with Tonix management. Perhaps I should notify the SEC and request an open investigation. If so, this individual is an insider influencing the stock price!!

Anyone wondering why this individual is strongly opposed to the forward split!!

Are the bigger 'players/institutionals' grabbing shares of TNXP?

5/23 the INST holding % was 7% of the 7.3 Mil shares

As of today, YAHOO FInance is still reporting 7% of the IMPLIED 8.3 Mil shares

But at $40+/sh?? Have to start wondering WHO is doing the buying. Been 5 minutes
so far this morn with over 15,000 shares 'traded' on the upswing in the price. Hmmm

AKA, be nice to see that INST holding % climb

All those in favor of a forward split of at least 10:1 add a thumbs up to this message.

Remember BOD has all the voting power and we got the short end of the stick. The BOD executed a 1:100 split instead of a stock buy back with funds they had on hand. The executives and BOD are sitting on millions while we get the shaft!! The 10:1 forward split is affordable and in the long run benefits the market cap and all stockholders. There is no reason a forward split cannot be done shortly!!

Look at the salaries that are being paid to the executives, millions. Are these people worth being paid millions for shortchanging the stockholders!!!!

Not a bad little breakout of approx 14% off the $35 level.

Tough to expect it to hold IF the move was based on the
PR regarding the MPOX vax.

Had to anticipate a pullback. The PR on the vax
is meaningless at this stage of its development.

But its a nice move up off the $34/35 range.

See if it can hold $37+now.. because of the closing in
PDUFA date...

disclaimer: still have an initial $50 target price on it IF
approved.. (then see what it can justify)

Anticipating a PDUFA decision delay??

NXRP and VSTM were due for a decision on 30 June.

Still waiting... Hmmm

disclaimer: Own shares in NRXP..(and of course, TNXP)

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Many investors might rightly wonder why companies announce splitting their stocks. After all, having more or less shares doesn’t change the overall picture for a company. From a mathematical perspective, a company that undertakes a stock split and those that don’t — like Berkshire Hathaway (NYSE:BRK-A, NYSE:BRK-B) via its A-class shares — should be valued on the same basis. And they are.

That said, the market views stock prices as important from a numerological perspective. Whether it’s to maintain a listing via a reverse split or increasing share count to broaden a company’s investor base, there are reasons for splits to take place.

Let’s dive into what stock splits are and why they matter. I’ll be focusing mostly on stock splits (increasing share count), but most of this commentary can be reversed for reverse stock splits.

Are Stock Splits Good for Stocks?
Companies typically undertake stock splits if they see their share prices are high and costly for investors to buy a standard amount (one full share, for example). Through the splits, the number of outstanding shares grows while the per-share price of a company’s stock declines. This improves liquidity and invites more options traders to the game.

More liquidity benefits both buyers and sellers, as the companies may allow buyback shares for more efficient and reduced costs.

While, theoretically, stock splits do not affect the value of a given company, they do often reignite investor interest that may help boost the underlying stock price. Investors in large companies, especially blue-chip ones, often see splits as bullish signals. That’s because these splits typically entail confidence about a given company’s future growth prospects.

Many top companies historically return to pre-split price levels, prompting subsequent splits. Walmart (NYSE:WMT), for instance, split its stock nine times on a 2-for-1 basis between 1975 and 1999, significantly multiplying shareholder holdings over three decades.

This strategy enhances marketability and liquidity, making it easier for smaller investors to participate, as seen with Amazon’s (NASDAQ:AMZN) 2022 split announcement coupled with a $10 billion share buyback.

Companies typically implement stock splits when their share prices become prohibitively high for new investors, signaling growth and future prospects positively. Post-split, stocks often experience price increases as lower nominal prices attract new investors.

Is It Better to Buy Stocks Before or After a Split?
Before deciding to buy a stock before or after a split, there are factors to consider. Such factors are current stock prices. Waiting until after a stock split may offer a more affordable entry point. However, the market has proven that buying before the split has added investor interest that can drive share prices in the long run.

For example, with 1,000 shares owned and valued at $10 each, and the company announces a stock 2-for-1 stock split, the investor would now own 2,000 shares with the same investment value of $10,000.

Each share would be valued at $5 post-split. However, dividends per share could decline after the split which will balance out the perceived advantage of share purchases before or after the split.

What Are the Disadvantages of a Stock Split?
While stock splits don’t affect the company’s fundamentals, they can still involve some losses and regulatory compliance. Despite dividing shares to lower the price, it doesn’t create additional value beyond enhancing market liquidity. This strategy is akin to slicing a cake — changing the number of pieces doesn’t alter the taste.

Implementing a stock split requires financial investment for regulatory compliance and legal support. However, it can attract a broader investor base, potentially diluting exclusivity for high-net-worth shareholders. Moreover, a stock split may reduce the face value of shares, posing risks if the company’s performance declines.

Conversely, a reverse stock split, although aimed at increasing share price, also entails legal and regulatory costs.

Furthermore, intentionally reducing a stock’s price can affect compliance with exchange rules like Nasdaq’s minimum trading price requirement, potentially leading to delisting if not rectified promptly.

Do Stocks Normally Go Up After a Stock Split?
Stock splits often attract investor attention, prompting companies like Tesla (NASDAQ:TSLA) to use them to generate buzz and attract more investors. Some companies regularly split stocks, which appeals to investors seeking to accumulate more shares. Although the split itself doesn’t change the stock’s value, investor enthusiasm often drives up prices after the announcement. In some cases, stocks may continue to rise even higher post-split.

Two main theories explain why companies opt for stock splits. Firstly, by reducing the share price, it becomes accessible to retail investors who may not have access to fractional shares. Secondly, high stock prices often restrict options trading, where contracts typically involve multiples of 100 shares. Lowering the share price through a split aims to increase investor participation and potentially drive up demand and the stock price.

The second theory suggests that a lower stock price enhances the chances of inclusion in price-weighted indexes like the Dow Jones Industrial Average. High-priced stocks are typically excluded from such indexes. Lowering the price increases the likelihood of index inclusion, prompting investors to anticipate these changes and buy the stock, potentially driving its price higher.

A stock split significantly improved trading conditions, reducing the bid-ask spread by 22%, increasing liquidity by 18% and lowering volatility by 3%, according to data compiled from the Nasdaq.

When Should a Company Do a Stock Split?
Most companies decide to do stock splits due to strategic considerations. When there has been a significant increase in stock value, companies consider splitting stocks to gain more investors. Research indicates that split stocks generally experience an average 7% increase in the first year and 12% growth over three years.

Some significant examples are companies like Apple (NASDAQ:AAPL). In 2014, the company traded at $600 per share, and the executives decided to have a stock split of 7-for-1. That reduced the share price to around $90 and improved Apple’s liquidity. Outstanding shares increased from 860 million to 6 billion.

At that time, the company had a $559 billion market cap, which increased to $562 billion after the split.

It won't be a $4.50 stock when the new drug is released. The pps will rise due to demand as I stated in one of my previous posts referring to Cisco. Also, initially the pps will open up more buyers at a heavier trade volume. As you stated only 7% is held by institutions. In the final analysis, the pps will be quite higher than $4.50. The reverse split only caused panic selling and angry investors!!!!

$TNXP anyone interested in the new TNX-102 SL Pain Medicine Journal article published on Tuesday here is a link:
https://doi.org/10.1093/pm/pnaf089

And here is a very nice little excerpt from the conclusion of the article:

"In conclusion, in this phase 3, randomised, placebo-controlled trial, treatment with TNX-102 SL was associated with significant improvements in core symptoms of widespread pain, disturbed sleep, and fatigue in patients with fibromyalgia and was generally safe and well tolerated. Results from this trial validate findings from a previous phase 3 trial, which also demonstrated efficacy in reducing pain with TNX-102 SL in fibromyalgia."

Bullish af!

Why would you want Tonix to be a $4.50 stock? Currently you only have 7% of the stock held by institutions. If Tonix became a $4.50 stock probably you will lose all or most all of that 7% as most Mutual Funds and Many other funds will NOT own stocks with price of less than $5.00
John k9uwa

Why

Now Tonix should announce a 10:1 forward split effective August , 2025 and this stock will fly...

Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results

July 10, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock rise 2% after unveiling new preclinical findings for its TNX-801 vaccine candidate at the 2025 Vaccine Congress in Vienna.

The biopharma company highlighted that its recombinant horsepox-based vaccine demonstrates promising potential to provide long-lasting immunity while being significantly more attenuated than earlier orthopoxvirus vaccines. Notably, the data showed that subcutaneous delivery of TNX-801 offers protection comparable to percutaneous administration, which the company intends to focus on for further development.

Preclinical results indicated that TNX-801 replicates 27 to 119 times less in primary human dermal cells than currently licensed vaccinia vaccines. In interferon receptor knockout mice, the vaccine exhibited up to a 100,000-fold reduction in virulence compared to traditional vaccines.

Additionally, a single dose of TNX-801 elicited robust binding and neutralizing antibody responses in various animal models, including immunocompromised subjects. Vaccinated macaques survived lethal exposure to Clade I mpox without developing lesions, and rabbits remained fully protected for over a year.

The vaccine candidate is being developed to help control mpox outbreaks and prepare for potential smallpox threats, with both the WHO and CDC maintaining mpox as a significant public health issue.

Tonix believes that TNX-801’s single-dose regimen could simplify outbreak management by removing the need for multiple immunizations required by existing vaccines.

https://ih.advfn.com/market-news/article/12408/tonix-pharmaceuticals-shares-climb-on-encouraging-tnx-801-vaccine-results

$TNXP

Now is the time for Tonix to announce a 10:1 forward split!!!

Wow... see a couple of headlines from yesterday, today (MPOX vax update).

Guessing the small FLOAT combined with some short positions and a little PR
in a market desperate for a potentially undervalued stock and it might explain
the pop on the open.

Or is there something else going on that hasn't been said outloud yet?

But I am going with some shorts having a rough morning cause they got
caught off guard.. (smile)

https://www.whitehouse.gov/articles/2025/05/president-trump-is-bringing-drug-manufacturing-back/
MABIGA

Still managing to hold onto the $34-35 range. Chart is showing a nice
flat lining around this level, BUT according to an indicator I use for 'sentiment'..
That 'flat lining' is fragile, ie, demand for the shares is 'tepid'.
Makes the share price 'easy' to be played with.

But TNXP is down to about a month now. Unfortunately, still
waiting for any word on 2 others who's decision date on the 30th
of June has slipped due to 'reported' shortages of staff at the FDA.

However in looking at a couple of others that had been delayed
(PDUFA dates of 6 and 17 June), they were just approved the last
couple of days.

So maybe the fda is 'catching up'.

I notice every time the company makes an announcement, the pps drops. The pps has gone up due to the anticipated release of the new drug!!!

I continue to encourage every stockholder to contact the company by email and phone demanding a forward split of 10:1!! The company owes us the forward split after taking our shares away. It's time we receive our forward split. Anyone know a great law firm that deals in stockholders getting short changed?

Interesting how the pps drops after Tonix announcement. If Tonix were to announce a forward split of 10:1 in a few days effective August 8, 2025, the pps would easily double. The management is only interested in their own incomes!!!!

This information is off the Tonix website. Show us something of substance like a forward split announced which Tonix owes to the shareholders after reducing our shares by a 1:100 split!!!

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Sina Bavari, PhD, Executive Vice President of Infectious Disease Research and Development at Tonix Pharmaceuticals, will present new data on TNX-801 (recombinant horsepox virus, live vaccine) at the upcoming Vaccine Congress 2025.
TNX-801 is a minimally replicative, attenuated live virus vaccine candidate designed to generate durable humoral and cellular immunity after a single dose. Preclinical results in animals have demonstrated protection against mpox and other orthopoxviruses, supporting further clinical evaluation. TNX-801 also serves as an orthopoxvirus vaccine platform that can deliver multiple protective antigens against diverse viral pathogens.

Dr. Bavari will present the safety, immunogenicity, and efficacy findings to date and describe Tonix’s plans to advance the TNX-801 platform into clinical trials to protect against mpox and other viral diseases.

Presentation details

Location: Vienna, Austria
Presentation Date / Time: July 10th / 11:20am GMT+2
Title: TNX-801, a single-dose live vaccine platform for Mpox and other emerging viral diseases: Safety, Immunogenicity, and Efficacy
Speaker: Sina Bavari, PhD, Tonix Pharmaceuticals

https://ih.advfn.com/stock-market/NASDAQ/tonix-pharmaceuticals-TNXP/stock-news/96382443/tonix-pharmaceuticals-announces-oral-presentation

The current OS should be over 10M shares at least and it will soon be further diluted to 20M shares based on the most recent TWICE HUGE Dilutions Going-On!

TNXP will crash to $2 or below to be fair considering that its OS will be diluted to 20M shares from 02/05/2025's Post-1:100 HUGE R/S 5M shares and current 52-week-low is $6.76!

The current Official shorting position is 1,130,000 shares.

I encourage all stockholders to contact Tonix by email and phone demanding Tonix announce a forward split of at least 10:1 to be effective before August 15, 2025!!! The Executive management is making millions off of us stockholders!!

Its not just TNXP.. Stocks that seem to be 'lightly' followed, low on
INSTITUTIONAL holdings (TNXP reportedly at 7%) seem to be
targets of the shorts and suspect algorithms set up to cycle the share
price for gains (both up and down).

I have another one CRMD that despite its growth profile, for over a year now
the INSTITUTIONAL holding % has defied 'logic' in that the institutions
have NOT been taking a position.

Its almost as if there is an agreement amongst Wall Street to avoid owing shares
so that someone else can have fun with the share price.

And the 'defying logic' comment comes from the aspect that the institutions
NORMALLY jump into a growth stock early on and ride it for some years.

TNXP at only 7% will be something to watch. And I suspect that IF its approved,
it has the chance to be the FOCUS drug for fibro treatment going forward. And a lot of
money will be lost by those selling the current, (yet reportedly ineffective) drugs available.

And that won't be well received by the big pharmas losing revenue..

it is always the same thing:
2025-07-03 56,885 + 620 = 57,505 / 126,093 = 45.61
2025-07-02 168,952 + 1,805 = 170,757 / 294,398 = 58.00
2025-07-01 267,329 + 4,742 = 272,071 / 608,489 = 44.71
2025-06-30 172,883 + 2,325 = 175,208 / 358,455 = 48.88

in this for days, the only day that the stock went down, was wenn the shorts was 58% 🤔

It is owed to the share holders since the greedy management with their million dollar salaries took a 1:100 reverse split and reduced our share count. Meanwhile they loaded their pockets with millions!!! Then the management mentioned they will sell $150 million in shares! How is that for a promise!!!!!!

When was that promised?

Attention all shareholders. Each person should contact Tonix by way of phone and email and demand a 10:1 forward split!!! These executives are doing quite well on our 1:100 reverse split!!!

Executive compensation for Tonix employees. Where is our 10:1 forward split!!!!
2022
For its 2023 fiscal year, TONIX PHARMACEUTICALS HLDG, listed the following executives on its annual proxy statement to the SEC
Equity
Cash Compensation
Other
Fiscal Year Ended in 2023
NAME AND TITLE TOTAL COMPENSATION PAY RANK BY TITLEIn Biotechnology industry
Seth Lederman
Chief Executive Officer $2,050,065View details
#464View more

Gregory Sullivan
Chief Medical Officer $951,998View details
#338View more

Jessica Morris
Chief Operations Officer $928,599View details
#124View more

Bradley Saenger

$904,913View details
#421




Data Year:
2024
2023
2022
For its 2023 fiscal year, TONIX PHARMACEUTICALS HLDG, listed the following executives on its annual proxy statement to the SEC

EquityCash CompensationOther
Fiscal Year Ended in 2023
Name And Title Total Compensation Pay Rank By Title
In Biotechnology industry
Seth Lederman
Chief Executive Officer
$2,050,065
View details
#464
View more
Gregory Sullivan
Chief Medical Officer
$951,998
View details
#338
View more
Jessica Morris
Chief Operations Officer
$928,599
View details
#124
View more
Bradley Saenger

Here shorts have always earned a lot!
43 days left!
I lean towards approval!
Someone will lose their mind.... if they don't tread carefully.

always the same story: stock down, a lot of shorts!!!!
2025-07-02 168,952 + 1,805 = 170,757 / 294,398 = 58.00
2025-07-01 267,329 + 4,742 = 272,071 / 608,489 = 44.71
2025-06-30 172,883 + 2,325 = 175,208 / 358,455 = 48.88
2025-06-27 255,009 + 810 = 255,819 / 449,410 = 56.92

you see here, 27/06/25 and 02/07/25 a lot of shorts, stock down again, it makes me 🤮

Where is our 10:1 forward split Tonix management??? You owe us a forward split of at least 10:1!!!!!!!

Your comments are timely with regard to what I just posted regarding the
bought and corrupted fda. For the very reasons you described, protecting
big pharmas interests/aka, money flow.

That said, I am expecting this one to be approved because there is nothing
that works, and that the medical community and those in the fibro community
appear to be aware of the development.

So we will see, but I have been in two MNKD and CRMD that got screwed over
by the fda to the tune of 4 years worth of delays.. and both of them had something
that made peoples lives better, they were/are revolutionary in how much better their
development was at the time (in MNKDs case) than the existing. CRMDs will
be the 'leader' in what it does for some time.. but even there, going to be intetresting
to see which companies choose to endanger their patients by continuing to use a lesser
product than what CRMD is capable of..

Disclaimer: just bought back a new round of shares in CRMD, its down at $12, with a target
price of $19/20.. and its a 'start' with regard to its long term potential.

One of the reasons I am really careful with regard to what bio I invest in. IF I can't trust the
studies, if they aren't 'simple' in nature (vs a complex development like alzheimers, cancers for example),
I hesitate to get involved. Cause those paying attention have long recognized our fed agencies have
been 'bought/corrupted' for money and power..

https://www.zerohedge.com/news/2025-07-01/fda-exposed-hundreds-drugs-approved-without-proof-they-work

FDA Exposed: Hundreds of Drugs Approved Without Proof They Work
By Maryanne Demasi, Brownstone Institute

The US Food and Drug Administration (FDA) has approved hundreds of drugs without proof that they work—and in some cases, despite evidence that they cause harm.

That’s the finding of a blistering two-year investigation by medical journalists Jeanne Lenzer and Shannon Brownlee, published by The Lever.

Reviewing more than 400 drug approvals between 2013 and 2022, the authors found the agency repeatedly ignored its own scientific standards.

One expert put it bluntly—the FDA’s threshold for evidence “can’t go any lower because it’s already in the dirt.”

A System Built on Weak Evidence
The findings were damning—73% of drugs approved by the FDA during the study period failed to meet all four basic criteria for demonstrating “substantial evidence” of effectiveness.

Those four criteria—presence of a control group, replication in two well-conducted trials, blinding of participants and investigators, and the use of clinical endpoints like symptom relief or extended survival—are supposed to be the bedrock of drug evaluation.

Yet only 28% of drugs met all four criteria—40 drugs met none.

These aren’t obscure technicalities—they are the most basic safeguards to protect patients from ineffective or dangerous treatments.

But under political and industry pressure, the FDA has increasingly abandoned them in favour of speed and so-called “regulatory flexibility.”

Since the early 1990s, the agency has...(READ THIS FULL ARTICLE HERE).

Yep thats what I figured. Target dates by the fda are meaningless. it comes down to the $$. they dont like new drugs that disrupt the money flow from big pharma. They are basically lynch pins for big pharma and large transnational food companies like kraft. there only job is to deny drugs and food by smaller companies to wipe out the competioion. I have a few shares here just in case but i doubt the drug ever gets approved. just my opinion.

Nope, not approved yet and at the moment, given a
few PFUDA dates have slipped already, odds are
it will continue to happen.

NRXP and VSTM were up yesterday, haven't heard
anything about their decisions (own shares of NRXP)

But TNXP is building a nice base around the $34/35 level..
and my primary trend indicator is showing a possible
interest for shares is developing (which one would expect to
see after a nice consolidation phase which is now in DAY 18..

been a while since i checked in here. have they approved the fibro. drug yet? have they delayed approval beyond august?

with a dollar this weak! This should be worth double!

https: //www.youtube.com/watch?v=WL1hlzLsUaU&list=RDWL1hlzLsUaU&start_radio=1

I think from now on, if the shorters keep quiet, Tonix wil rise again 😀

value_investor : you are talking bulshit, on with side are you???
there is 150:000000$ invested so let's say 150:000:000/25 = 6M shares and not 20M!!
Stop talking bulshit, that's just not ok 🤮

TNXP crashed to $22.3 on the After-Hour session of June 11!

LOL, the target $61.67 is based on the 7,324,670 shares OLD OS! That target will be Significantly Lowered to $22.51 since the OS will soon be Heavily-Diluted to about 20M shares!

June 11's AH-Low $22.3 will be tested again in the coming week...

Don't forget that the current 52-week-low $6.76 was just created a few months ago from the chart below!

Anyway, the Upcoming New 52-week-low will be $2.25 ~ $0.5215 (to match its extra-Nasdaq peer's Same crashing performance after 1:20 R/S --- from $10.374 to $0.0417) based on the TRIPLE OS Dilutions!

The OS was only 5,261,641 shares right after Feb 5's 1:100 HUGE R/S!

The Crap CEO should be sent to the jail FOREVER for what he did to destroy all the TNXP investors!